Mike Petroutsas, president and head of U.S. commercial at Astellas, explores the importance of insight-driven ...
In today’s Pharmaceutical Executive Daily, the FDA grants breakthrough therapy designation to baxdrostat for uncontrolled hypertension, a wave of leadership departures leaves the FDA facing renewed ...
Makary’s departure followed internal disputes over approval decisions and Covid-19 vaccine posture, catalyzing a rapid ...
Toragen’s partnership with the Bill & Melinda Gates Foundation highlights how global health priorities and commercial biotech ...
Dr. Richard Graham explains how FDA’s new program allows for the usage of real-time data during clinical trials. In April, ...
Biotech’s ~10-year path from private risk to approved therapy is mismatched with trading-driven capital markets, where minor ...
Pharmaceutical Executive: How are pharma companies adjusting strategies for changing FDA dynamics? David Crean: FDA is ...
A $125 million near-term package comprises $50 million upfront and a $75 million equity commitment, with total potential value up to $2.325 billion including milestones and tiered low–double-digit ...
Baxfendy is indicated as add-on therapy for adults inadequately controlled on other antihypertensives, with recommended dosing of 2 mg daily and 1 mg daily for higher ...
Neoadjuvant approval uses four cycles of trastuzumab deruxtecan followed by THP, improving pCR to 67.3% versus 56.3% with ddAC→THP (absolute +11.2%; P=.003). Adjuvant approval in post-neoadjuvant ...
In today's Pharmaceutical Executive Daily, FDA approves AstraZeneca's Fasenra as a new treatment for hypereosinophilic ...
According to him, the industry must address its relationship with the capital markets, address misinformation issues, and push back against the politicization of medical research and development.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results